Company Filing History:
1 out of 45 
1 out of 78 Years Active: 2014
Title: Andrei Chapoval: Innovator in Monoclonal Antibodies
Introduction
Andrei Chapoval is a notable inventor based in Towson, MD (US), recognized for his contributions to the field of biotechnology. He has developed innovative solutions in the realm of monoclonal antibodies, particularly focusing on GPNMB.
Latest Patents
Chapoval holds a patent for "Antibodies directed to GPNMB and uses thereof." This invention provides fully human monoclonal antibodies that specifically bind to GPNMB, along with their various applications. The patent includes nucleotide sequences encoding heavy and light chain immunoglobulin molecules, particularly those corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs). Additionally, the invention encompasses immunoconjugates comprising anti-GPNMB antibodies and methods for utilizing such immunoconjugates. Furthermore, it introduces bi-specific antibodies that include an anti-GPNMB antibody component and an anti-CD3 component, along with methods for their application.
Career Highlights
Throughout his career, Andrei Chapoval has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Celldex Therapeutics Limited and Amgen Fremont Inc. His work in these organizations has significantly contributed to advancements in therapeutic antibody development.
Collaborations
Chapoval has collaborated with esteemed colleagues in his field, including Feng Xiao and Xiao-Chi Jia. These partnerships have fostered innovation and progress in the research and development of monoclonal antibodies.
Conclusion
Andrei Chapoval's work in the development of antibodies directed to GPNMB showcases his innovative spirit and dedication to advancing biotechnology. His contributions continue to impact the field positively.